

Emerging Medical Technologies

Celimar Valentin-Rodriguez, PhD
Medical Team Leader
US Nuclear Regulatory Commission
June 8, 2023

Outline



Regulatory Background



Guidance Development Process



Emerging Medical Technologies



Rulemaking

EMT Regulatory Background

- In 2002, the Commission added 10 CFR 35.1000 to add *generic requirements* for new medical uses of byproduct material or radiation from byproduct material (**EMTs**)
- 10 CFR 35.1000 allows the NRC and Agreement States to regulate medical uses that are not otherwise addressed in 10 CFR Part 35 on a case-by-case basis



Standing Committee on Reviewing Emerging Medical Technologies

- Established in 2020
- Assist NRC staff in evaluating the licensing of EMTs and provide early feedback on draft documents
- Includes members from
 - MRST
 - NRC Regions
 - OGC
 - Agreement States



Evaluation & Guidance Development Process



EMT Evaluations

- Since 2002
 - reviewed more than 16 EMTs
 - issued 12 licensing guidance documents
 - issued 3 licensing memoranda
- Licensing guidance is revised as needed, as we gain operating experience with EMTs



Brachytherapy




Y-90 Microspheres

Hepatocellular carcinoma
and other cancers



Alpha DaRT

Solid tumors



Liberty Vision Y-90 Disc Sources

Episcleral ocular diseases,
tumors, and benign growths

Gamma Stereotactic Radiosurgery



Icon, Perfexion, Esprit

Tumors, vascular and neurological disorders



Akesis Galaxy RTi


Cancer and intracranial diseases



Xcision GammaPod

Breast cancer

Radiopharmaceuticals (\$35.300)



The image shows a green plastic vial and a small glass vial of Lutathera. The green vial has a white label with black text and a yellow biohazard symbol. The glass vial is clear with a white label and a silver cap.

LUTATHERA
(Lu-177 dotatate)
GEP-NETs



The image shows a green plastic vial and a small glass vial of Pluvicto. The green vial has a white label with black text and a yellow biohazard symbol. The glass vial is clear with a white label and a silver cap.


PLUVICTO
(Lu-177 PSMA)
PSMA-positive mCRPC



The image shows a large grey vial and a small white vial of Xofigo. The large vial has a white label with black text and a yellow biohazard symbol. The small vial is white with a white label and a white cap.


Xofigo
(Ra-223 dichloride)
MCRPC
(bone metastasis)

Brachytherapy (§35.400)



GammaTile


Brain tumors



CivaDerm

Skin cancer and other
lesions

EMT/Rb-82 Generator Rulemaking



Acronyms

- CFR – Code of Federal Regulations
- EMT – emerging medical technology(ies)
- GEP-NETs – gastroenteropancreatic neuroendocrine tumors
- Lu-177 – lutetium-177
- MRST – Medical Radiation Safety Team
- mCRPC – metastatic castration-resistant prostate cancer
- PSMA – prostate-specific membrane antigen
- Ra-223 – radium-223
- Rb-82 – rubidium-82
- OGC – Office of the General Counsel
- SRM – staff requirements memorandum
- WG – working group
- Y-90 – yttrium-90



Contact Us!



Celimar.Valentin-Rodriguez@nrc.gov



medicalquestions.resource@nrc.gov



301-415-7124



[Medical Uses Licensee Toolkit | NRC
Public Website](#)

